111 related articles for article (PubMed ID: 20537666)
1. [Evaluation of the effectiveness of treatment with rituximab associated to cyclophosphamide in patients with resistant idiopathic inflammatory myopathy].
García Hernández FJ; Chinchilla Palomares E; Castillo Palma MJ; González Pulido C; Ocaña Medina C; Sánchez Román J
Med Clin (Barc); 2010 Jul; 135(6):256-9. PubMed ID: 20537666
[TBL] [Abstract][Full Text] [Related]
2. Rituximab as an effective alternative therapy in refractory idiopathic inflammatory myopathies.
Muñoz-Beamud F; Isenberg DA
Clin Exp Rheumatol; 2013; 31(6):896-903. PubMed ID: 24050676
[TBL] [Abstract][Full Text] [Related]
3. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial.
Jones RB; Furuta S; Tervaert JW; Hauser T; Luqmani R; Morgan MD; Peh CA; Savage CO; Segelmark M; Tesar V; van Paassen P; Walsh M; Westman K; Jayne DR;
Ann Rheum Dis; 2015 Jun; 74(6):1178-82. PubMed ID: 25739829
[TBL] [Abstract][Full Text] [Related]
4. [Biologic agents in myositis: unsolved questions].
Grau JM; Prieto-González S
Med Clin (Barc); 2010 Jul; 135(6):263-4. PubMed ID: 20451933
[No Abstract] [Full Text] [Related]
5. Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life population.
Unger L; Kampf S; Lüthke K; Aringer M
Rheumatology (Oxford); 2014 Sep; 53(9):1630-8. PubMed ID: 24706995
[TBL] [Abstract][Full Text] [Related]
6. Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis?
Li EK; Tam LS; Zhu TY; Li M; Kwok CL; Li TK; Leung YY; Wong KC; Szeto CC
Rheumatology (Oxford); 2009 Aug; 48(8):892-8. PubMed ID: 19478041
[TBL] [Abstract][Full Text] [Related]
7. Cyclophosphamide treatment of interstitial pulmonary fibrosis in polymyositis/dermatomyositis.
al-Janadi M; Smith CD; Karsh J
J Rheumatol; 1989 Dec; 16(12):1592-6. PubMed ID: 2625692
[TBL] [Abstract][Full Text] [Related]
8. Rituximab (MABTHERA) and severe polyangiitis. An option for patients informed of the uncertainties.
Prescrire Int; 2015 Jun; 24(161):145-8. PubMed ID: 26436161
[TBL] [Abstract][Full Text] [Related]
9. [Therapeutic strategies in idiopatic inflammatory myopathies].
Chakour R; Leimgruber A; Bart PA; Spertini F
Rev Med Suisse; 2009 Apr; 5(199):812-8. PubMed ID: 19441746
[TBL] [Abstract][Full Text] [Related]
10. Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study.
Moroni G; Raffiotta F; Trezzi B; Giglio E; Mezzina N; Del Papa N; Meroni P; Messa P; Sinico AR
Rheumatology (Oxford); 2014 Sep; 53(9):1570-7. PubMed ID: 24505125
[TBL] [Abstract][Full Text] [Related]
11. B-cell depletion with rituximab for refractory head and neck Wegener's granulomatosis: a cohort study.
Martinez Del Pero M; Chaudhry A; Jones RB; Sivasothy P; Jani P; Jayne D
Clin Otolaryngol; 2009 Aug; 34(4):328-35. PubMed ID: 19673980
[TBL] [Abstract][Full Text] [Related]
12. Rituximab as a first-line agent for the treatment of dermatomyositis.
Haroon M; Devlin J
Rheumatol Int; 2012 Jun; 32(6):1783-4. PubMed ID: 20340018
[TBL] [Abstract][Full Text] [Related]
13. Rituximab in the treatment of refractory dermatomyositis.
Chiappetta N; Steier J; Gruber B
J Clin Rheumatol; 2005 Oct; 11(5):264-6. PubMed ID: 16357773
[TBL] [Abstract][Full Text] [Related]
14. Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy.
Roccatello D; Sciascia S; Rossi D; Alpa M; Naretto C; Baldovino S; Menegatti E; La Grotta R; Modena V
Nephrol Dial Transplant; 2011 Dec; 26(12):3987-92. PubMed ID: 21385860
[TBL] [Abstract][Full Text] [Related]
15. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial.
Iijima K; Sako M; Nozu K; Mori R; Tuchida N; Kamei K; Miura K; Aya K; Nakanishi K; Ohtomo Y; Takahashi S; Tanaka R; Kaito H; Nakamura H; Ishikura K; Ito S; Ohashi Y;
Lancet; 2014 Oct; 384(9950):1273-81. PubMed ID: 24965823
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and limitations of pulse cyclophosphamide therapy in polymyositis and dermatomyositis.
Nagappa M; Taly AB; Sinha S; Gayathri N; Bindu PS; Mahadevan A; Yasha T
J Clin Neuromuscul Dis; 2013 Jun; 14(4):161-8. PubMed ID: 23703010
[TBL] [Abstract][Full Text] [Related]
17. Successful treatment of pemphigus with biweekly 1-g infusions of rituximab: a retrospective study of 47 patients.
Leshem YA; Hodak E; David M; Anhalt GJ; Mimouni D
J Am Acad Dermatol; 2013 Mar; 68(3):404-11. PubMed ID: 23044076
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of rituximab in refractory antisynthetase syndrome.
Limaye V; Hissaria P; Liew CL; Koszyka B
Intern Med J; 2012 Mar; 42(3):e4-7. PubMed ID: 22432998
[TBL] [Abstract][Full Text] [Related]
19. Rituximab treatment in patients with refractory inflammatory myopathies.
Mahler EA; Blom M; Voermans NC; van Engelen BG; van Riel PL; Vonk MC
Rheumatology (Oxford); 2011 Dec; 50(12):2206-13. PubMed ID: 21571768
[TBL] [Abstract][Full Text] [Related]
20. [The role of rituximab in the treatment of ANCA-associated systemic vasculitis].
Roccatello D; Vangelista A; Pani A
G Ital Nefrol; 2011; 28(5):474-88. PubMed ID: 22028261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
